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Supplementary Figure S1. Stapled ERAP suppresses the E2-dependent 
long-term responsiveness. (a) Percent growth inhibition of 10 nM E2-dependent 
MCF-7 cells and mammary epithelial MCF-10A cells by ERAP and its stapled analogs. 
(b) An MTT assay evaluating the inhibitory effects of stERAPs and unstapled, original 
ERAP on the growth of MCF-10A cells. Cells were given a single treatment at 0 h. 
These data represent the mean ± s.d. of three independent experiments. (c) Heat-map 
image representing 284 genes that were significantly up-regulated or down-regulated > 
100-fold in stERAP-5 compared to stERAP-2 at 48 h post treatment. (d) Upper panel, 
gene annotation enrichment analysis based on DAVID. Lower panel, pathway analysis 
based on GeneMANIA software. (e) The duration of the inhibitory effects of stERAPs on 
ER-target gene expression in MCF-7 cells. The results were expressed as the fold 
increase over untreated cells at 0 h (set at 1.0). The data represent the mean ± s.e.m. of 
three independent experiments. **P < 0.01 and ***P < 0.001 via two-sided Student's 
t-tests. 
 
 
 
 
 
Supplementary Figure S2. HA-stERAP-6 suppresses the E2-dependent 
responsiveness. (a, b) MTT assays evaluating the inhibitory effects of HA-stERAP-6 
(a) linear ERAP (b) on 10 nM E2-dependent growth of MCF-7 cells. Cells were given a 
single treatment at 0 h. These data represent the mean ± s.d. of three independent 
experiments. ***P < 0.001 via a two-sided Student's t-test. 
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Supplementary Figure S3. StERAP-6 inhibits tumour growth in xenograft 
models of human ER-positive breast cancer. (a) Schematic illustrations of in 
vivo experiments. (b) Representative HE staining of vital organs, including the 
heart, lung, liver, kidney, pancreas, and brain from mice treated daily with 14 mg 
kg-1 stERAP-6 for 28 days. (c) The body weights of the KPL-3C xenograft mice 
via intraperitoneally treatment daily or every 4 days with unstapled, original 
ERAP (left) and stERAP-6 (right) at 14 mg kg-1. The body weights represent the 
mean ± s.d. of each group (n = 5). (d) Immunoblot analysis detecting the 
subcellular localization of BIG3 and PHB2 in tumours treated intraperitoneally 
daily (left) and every 4 days (right) with stERAP-6 or ERAP. /-tubulin (Tublin) 
and laminin B were used as loading controls for the cytoplasmic and nuclear 
fractions, respectively. (e) The body weights of the KPL-3C xenograft mice via 
intravenously treatment of stERAP-6 with daily (left) and weekly treatments 
(right). The body weights represent the mean ± s.d. of each group (n = 5). (f) 
Tumour growth by daily intravenous injection of alanine-mutant stERAP-6 in 
KPL-3C xenograft mice. The tumour sizes represent the mean ± s.e.m. of each 
group (n = 4). (g) Immunoblot analysis of the binding inhibition of BIG3-PHB2 in 
tumours treated intravenously daily (left) and weekly (right) with stERAP-6. (h) 
The potential chymotrypsin cleavage site of ERAP sequence using the Expasy 
PeptideCutter program. (i) Blood-brain barrier (BBB) permeability of stERAP-6. 
(j) mRNA expression of BIG3 in patients with ER-positive endometrial cancer 
based on the TCGA data set (left) and Gene Expression Omnibus database 
(GSE17025, right).  
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Supplementary Figure S4. Schematic illustrations of stapled ERAP 
synthesis. (a) Stapling synthesis of ERAP by ring-closing olefin metathesis. (b) 
Stapling synthesis of ERAP via intramolecular amidation. (c) Reagents and 
conditions of amino acid synthesis: (i) 2,4-dimethoxybenzaldehyde, AcOH, 
MgSO4, and CH2Cl2; (ii) NaBH4, MeOH, CH2Cl2; (iii) 2, EDC-HCl, DIPEA, CH2Cl2 
(iv) LiOH·H2O, THF, MeOH, H2O; (v) TBSOTf, 2,6-lutidine, CH2Cl2; and (vi) 
Fmoc-OSu, Na2CO3, THF, H2O. 
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Supplementary Figure S5. Full-length images of immunoblots. Uncropped 
images of scanned immunoblots in Figures and Supplementary figures with size 
marker indications (kDa). 
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Supplementary Methods 
Amino acids synthesis 
For column chromatography, Silica Gel 60 N (spherical; neutral; particle size 
range: 63–210 nm; KANTO CHEMICAL, Tokyo, Japan) was employed. Mass 
spectra were recorded on a Waters MICROMASS® LCT PREMIERTM (ESI-TOF). 
NMR spectra were measured using a JEOL GSX300 spectrometer. For HPLC 
separation, a Cosmosil 5C18-AR-II analytical column (4.6 × 250 mm, flow rate 1 
mL/min, Nacalai Tesque, Kyoto, Japan) and a Cosmosil 5C18-AR-II semi 
preparative column (10 × 250 mm, flow rate 3.0 mL/min, Nacalai Tesque) was 
employed, and eluting products were detected by UV at 220 nm. A solvent 
system consisting of 0.1% (v/v) TFA aqueous solution (solvent A) and 0.1% (v/v) 
TFA in MeCN (solvent B) was used for HPLC elution over 30 min. Optical 
rotation was determined on a JASCO P2200 polarimeter. 
Amino acid synthesis was performed as shown in Supplementary Figure 
S4C.1 Briefly, 2,4-dimethoxybenzaldehyde (781 mg, 4.70 mmol), MgSO4 (2.26 g, 
18.8 mmol), and AcOH (26.9 mL, 0.47 mmol) were added to a solution of allyl 
(4-aminobutyl) carbamate (1) (810 mg, 4.7 mmol) in MeOH (47 mL). The 
resulting mixture was stirred at room temperature for 3 h and filtered to remove 
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MgSO4. The obtained reaction mixture was cooled to 0°C, and NaBH4 (355 mg, 
9.4 mmol) was added. The solution was warmed to room temperature and 
stirred for 1 h. The reaction mixture was quenched with 5% (w/v) aqueous 
solution of KHSO4. The solution was basified with a saturated aqueous solution 
of NaHCO3, and the mixture was extracted with EtOAc. The organic layer was 
washed with brine, dried over MgSO4, and filtered. After concentration in vacuo, 
the crude product was purified by column chromatography (CHCl3/MeOH = 30:1 
(v/v)) and 1.32 g of amine (2) (allyl [4-{(2,4-dimethoxybenzyl)amino}butyl] 
carbamate, 4.09 mmol, 87%) was obtained as a pale yellow oil: 1H NMR (CDCl2, 
300 MHz)  = 1.42–1.58 (4H, m), 2.56 (2H, t, J = 6.7 Hz), 3.15 (2H, dt, J = 6.0 
and 6.0 Hz), 3.67 (2H, s), 3.77 (3H, s), 3.78 (3H, s), 4.52 (2H, d, J = 5.5 Hz), 5.17 
(1H, ddt J = 10.5, 1.5, and 1.5 Hz), 5.27 (1H, ddt J = 17.3, 1.5, and 1.5 Hz), 5.35 
(1H, br s), 5.89 (1H, ddt, J = 17.3, 10.5, and 5.5 Hz), 6.40 (1H, dd, J = 8.1 and 
2.4 Hz), and 6.43 (1H, d, J = 2.4 Hz), 7.09 (1H, d, J = 8.1 Hz); 13C NMR (CDCl2, 
75 MHz) 5 = 27.4, 27.9, 41.0, 48.6, 48.9, 55.3, 55.4, 65.4, 98.6, 103.7, 117.4, 
120.9, 130.5, 133.2, 156.4, 158.6, and 160.1; HRMS (ESI-TOF) m/z calcd for 
C17H27N2O4 ([M + H]+): 323.1971, found: 323.1963.  
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The resultant amine (2) (1.22 g, 3.78 mmol), 
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl) (798 
mg, 4.16 mmol), and diisopropylethylamine (DIPEA) were added to a solution of 
N--(t-butoxycarbonyl)-L-glutamic acid -methyl ester (3) in 1,2-dichloroethane 
(18.9 mL) at 0°C. The mixture was stirred at room temperature for 5 h. After the 
addition of 5% (w/v) KHSO4, the reaction mixture was extracted with EtOAc. The 
organic layer was washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude product was purified by column 
chromatography (hexane/EtOAc = 1:2 (v/v)), and 1.62 g of amide (4) 
((S)-Methyl-5-{(4-[{(allyloxy)carbonyl}amino]butyl)(2,4-dimethoxybenzyl)amino}-
2-{(tert-butoxycarbonyl)amino}-5-oxopentanoate, 2.86 mmol, 76%) was 
obtained as a pale yellow oil: []19D-5.33 (c 1.24, MeOH); 1H NMR (DMSO-d6, 
300 MHz, 80°C)  = 1.38 (9H, s), 1.27–1.53 (2H, m), 1.27–1.53 (2H, m), 1.46–
1.92 (1H, m), 1.92–2.10 (1H, m), 2.42 (2H, dt, J = 4.5 and 6.6 Hz), 2.97 (2H, dt, J 
= 6.0 and 6.3 Hz), 3.19 (2H, br t, J = 7.0 Hz), 3.62 (3H, s), 3.76 (3H, s), 3.80 (3H, 
s), 3.94–4.14 (1H, m), 4.39 (2H, br s), 4.46 (2H, ddd, J = 5.5, 1.7, and 1.3 Hz), 
5.16 (1H, ddt, J = 10.4, 1.8, and 1.3 Hz), 5.26 (1H, ddt, J = 17.2, 1.8, and 1.7 Hz), 
5.90 (1H, ddt, J = 17.2, 10.4, and 5.5 Hz), 6.39–6.53 (1H, br m), 6.53–6.63 (1H, 
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br m), 6.70–6.92 (2H, br m), 6.96 (1H, br d, 7.9 Hz); 13C NMR (DMSO-d6, 75 
MHz, 80°C)  = 24.0, 25.2, 26.4, 26.5, 27.8, 28.3, 41.6, 44.4, 45.3, 46.1, 51.1, 
53.1, 54.9, 55.1, 63.7, 77.9, 78.7, 98.4, 104.7, 116.3, 117.0, 128.0, 128.8, 133.5, 
154.9, 155.5, 157.8, 159.5, 159.8, 171.0, 172.4; HRMS (ESI-TOF) m/z calcd for 
C28H43N3NaO9 ([M + Na]+): 588.2897, found: 588.2902.  
To a solution of amide 4 in THF (5 mL), LiOH·H 2O (91.8 mg, 2.18 mmol), 
MeOH (2.5 mL), and H2O (2 mL) were added at 0°C, and the reaction mixture 
was stirred for 2 h. The reaction was quenched by the addition of 5% (w/v) 
KHSO4, and the reaction mixture was extracted with EtOAc. The organic phase 
was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
The residue was purified by column chromatography (CHCl3/MeOH = 50:1–10:1 
(v/v), containing 0.1% (v/v) AcOH) to yield 747 mg of carboxylic acid (5) 
((S)-5-((4-(((Allyloxy)carbonyl)amino)butyl)(2,4-dimethoxybenzyl)amino)-2-((tert-
butoxycarbonyl)amino)-5-oxopentanoic acid, 1.35 mmol, 92%) as a white 
powder: []18D -0.65 (c 0.950, MeOH); 1H NMR (DMSO-d6, 300 MHz, 80°C)  = 
1.39 (9H, s), 1.27–1.53 (2H, m), 1.27–1.53 (2H, m), 1.76–1.94 (1H, m), 1.94–
2.13 (1H, m), 2.44 (2H, dt, J = 7.5 and 4.2 Hz), 2.99 (2H, dt, J = 6.3 and 6.1 Hz), 
3.20 (2H, br t, J = 7.1 Hz), 3.76 (3H, s), 3.80 (3H, s), 3.89–4.08 (1H, m), 4.41(2H, 
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br s), 4.47 (2H, ddd, J = 5.4, 1.5, and 1.5 Hz), 5.16 (1H, ddt, J = 10.5, 1.7, and 
1.5 Hz), 5.26 (1H, dt, J = 17.4, 1.7, and 1.5 Hz), 5.90 (1H, ddt, J = 17.4, 10.5, 
and 5.4 Hz), 6.38–6.53 (1H, br m), 6.56 (1H, br s), 6.66 (1H, br s), 6.78 (1H, br s), 
6.98 (1H, br d, J = 8.1 Hz); 13C NMR (DMSO-d6, 75 MHz, 80°C)  = 24.2, 25.3, 
26.6, 26.7, 27.9, 28.6, 39.9, 41.8, 44.4, 45.4, 46.3, 53.1, 55.0, 55.2, 63.8, 77.8, 
98.5, 104.8, 116.3, 117.1, 117.8, 128.1, 128.8, 133.5, 155.1, 155.6, 157.9, 159.6, 
159.9, 171.3, 173.3; HRMS (ESI-TOF) m/z calcd for C27H41N3NaO9 ([M + Na]+): 
574.2741, found: 574.2740. 
tert-Butyldimethylsilyl trifluoromethanesulfonate (TBSOTf) (1.04 mL, 4.5 mmol) 
and 2,6-lutidine (787 L, 6.75 mmol) were added to a solution of Boc derivative 5 
(621 mg, 1.13 mmol) in CH2Cl2 (11.3 mL) at 0°C. The reaction mixture was 
warmed to room temperature slowly and stirred for 4 h. The solution was 
concentrated in vacuo and then diluted with THF (8 mL). After the solution was 
neutralized with 2 M aqueous solution of NaOH (2 mL) at 0°C, 10% (w/v) 
Na2CO3 (8 mL) and Fmoc-OSu (572 mg, 1.7 mmol) were added to the solution. 
After 12 h stirring at room temperature, the mixture was acidified with 1 M 
aqueous solution of HCl and extracted with EtOAc. The organic layer was 
washed with brine, dried over Na2SO4, filtered, and concentrated. The residue 
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was purified by column chromatography (CHCl3/MeOH = 50:1–10:1 (v/v), 
containing 0.1% (v/v) AcOH) to yield (6) 
((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((4-(((allyloxy)carbonyl)am
ino)butyl)(2,4-dimethoxybenzyl)amino)-5-oxopentanoic acid, 680 mg, 1.01 mmol, 
90%) as a white powder: []19D +8.38 (c 1.13, MeOH); 1H NMR (DMSO-d6, 300 
MHz, 80°C)  = 1.29–1.61 (4H, m), 1.87–2.02 (1H, m), 2.03–2.21 (1H, m), 2.45-
2.56 (2H, m), 3.00 (2H, dt, J = 6.0 and 6.4 Hz), 3.23 (2H, br t, J = 6.6 Hz), 3.74 
(3H, s), 3.79 (3H, s), 4.05–4.18 (1H, m), 4.22 (1H, t, J = 6.6 Hz), 4.31 (2H, d, J = 
6.6 Hz), 4.43 (1H, br s), 4.48 (2H, ddd, J = 5.7, 1.7, and 1.5 Hz), 5.12 (1H, ddt, J 
= 10.2, 1.7, and 1.5 Hz), 5.27 (1H, ddt, J = 17.1, 1.7, and 1.7 Hz), 5.91 (1H, ddt, 
J = 17.1, 10.2, and 5.7 Hz), 6.42–6.52 (1H, br m), 6.56 (1H, d, J = 2.1 Hz), 6.80 
(1H, br s), 6.91–7.10 (1H, br m), 7.31 (2H, t, J = 7.5 Hz), 7.40 (2H, t, J = 7.2 Hz), 
7.70 (2H, br d, J = 7.2 Hz), 7.85 (2H, d, J = 7.5 Hz); 13C NMR (DMSO-d6, 75 MHz, 
80°C)  = 24.2, 25.3, 26.6, 28.6, 39.9, 41.8. 44.3, 45.3, 46.6, 53.4, 54.9, 55.1, 
63.8, 65.6, 98.4, 104.7, 108.6, 116.3, 117.0, 117.7, 119.6, 120.9, 124.8, 126.6, 
126.6, 126.8, 127.2, 128.2, 128.5, 128.9, 133.5, 139.2, 140.4, 140.4, 143.6, 
143.6, 155.6, 155.6, 157.8, 159.6, 159.9, 171.2, 173.1; HRMS (ESI-TOF) m/z 
calcd for C37H43N3NaO9 ([M + Na]+): 696.2897, found: 696.2928. 
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Cell lines and culture conditions. A human breast cancer cell line, MCF-7, and 
a mammary epithelial cell line, MCF-10A, were purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA). The KPL-3C cells were 
established, characterized, and kindly provided by Dr. Jun-ichi Kurebayashi 
(Kawasaki Medical School).2 All cell lines were cultured as monolayers in an 
appropriate medium supplemented with 10% FBS. Cells were maintained at 
37°C in an atmosphere of humidified air with 5% CO2. The MCF-7 cells were 
seeded in 48-well plates (2 × 104 cells/mL), 6-well plates (3 × 105 cells/mL), or 
10-cm dishes (2 × 106 cells/mL) in MEM (Life Technologies, Rockville, MD, 
USA) supplemented with 10% FBS (Nichirei Biosciences, Tokyo, Japan), 1% 
antibiotic/antimycotic solution (Life Technologies), 0.1 mM NEAA (Life 
Technologies), 1 mM sodium pyruvate (Life Technologies), and 10 ng/mL insulin 
(Sigma). KPL-3C cells were seeded in RPMI (Life Technologies) supplemented 
with 10% FBS and 1% antibiotic/antimycotic solution. MCF-10A cells were 
seeded in MEBM (Lonza, Walkersville, MD, USA) supplemented with 
SingleQuots Kit (BPE, hydrocortisone, hEGF, insulin, and 
gentamicin/amphotericin-B) and 100 ng/mL cholera toxin. For 17-estradiol (E2, 
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Sigma) stimulation in MCF-7 and KPL-3C cells, the medium was changed the 
next day to phenol red-free DMEM/F12 (Life Technologies) supplemented with 
FBS, antibiotic/antimycotic solution, NEAA, sodium pyruvate, and insulin. After 
24 h, the cells were treated with 10 nM E2 ± peptides (e.g., ERAP or stapled 
ERAP). 
 
Microarray analysis. Total RNA was purified with the NucleoSpin RNA II 
system (Takara-Clontech) according to the manufacturer's instructions. For RNA 
amplification and labeling, we used an Agilent Low-Input QuickAmp labeling kit 
(Agilent Technologies). Briefly, 100 ng of total RNA from each sample was 
amplified using T7 RNA polymerase with simultaneous Cy3-labeled CTP 
incorporation. Then, 600 ng of Cy3-labeled cRNA was fragmented, hybridized 
onto the Agilent Whole Human Genome Microarray 8 × 60K slide (Agilent 
Technologies), and incubated with rotation at 65°C for 18 h. The slides were 
washed and scanned using an Agilent Microarray scanner system in an ozone 
protection fume hood. The scanned image files containing the Cy3-fluorescence 
signals were extracted using the Agilent Feature Extraction (version 9.5, Agilent 
Technologies). The data were analyzed using GeneSpring (version 13.0). We 
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normalized the microarray data across all chips and genes by quantile 
normalization, and transformed the signal values to the median in all samples. To 
identify genes that were significantly altered, the mean signal intensity values in 
each analysis were compared. 
 
Functional gene annotation clustering. DAVID 6.7 (refs. 3,4) and geneMANIA 
database, which is based on the Cytoscape plugin,5 were approved to detect 
functional gene annotation clusters based on expression profiling by gene 
annotation enrichment analysis. 
 
The morphological evaluation of xenograft model. To examine the 
morphological changes in each organ (heart, lung, liver, kidney, pancreas, and 
brain) of xenograft mice, the specimens were fixed in 10% phosphate-buffered 
formalin, embedded in paraffin, cut at 4 m thickness and stained with 
hematoxylin and eosin. Registered pathologists (YO and ST) evaluated the 
morphological changes in vital organs of mice. 
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Prediction of chymotrypsin cleavage site of stERAP-6. Potential 
chymotrypsin (EC 3.4.21.1) cleavage site of stERAP-6 was predicted using the 
Expasy PeptideCutter program 
(http://ca.expasy.org/cgi-bin/peptidecutter/peptidecutter.pl). 
 
In vitro blood-brain barrier (BBB) model. To investigate the ability of ERAP 
and stERAP to penetrate into the central nervous system, the BBB kit 
(RBT24-H) was used as an in vitro BBB model (PharmaCo-Cell, Nagasaki, 
Japan) as previously described.6,7 This BBB model was reconstructed using 
cultured primary rat brain microvascular endothelial cells and rat brain pericytes 
separated by a macroporous Millicel membrane (24 wells, pore size: 3.0 m, 
Millipore, Bedford, MA, USA). Briefly, FITC-tagged stERAP-6, suspended in 0.2 
mL assay medium (10 mM HEPES and 25 mM D-glucose in PBS), was added 
into the luminal side and incubated for 30 min. We collected the medium at the 
abluminal sides. The fluorescence intensity of FITC-stERAP-6 that permeated 
the abluminal sides was measured with a Micro-plate Reader Infinite 200 (Tecan, 
Mannedorf, Switzerland). The permeability coefficient (Papp) was calculated 
using a formula provided by Pharmaco-Cell Company Ltd. 
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BIG3 expression in endometrial cancer. BIG3 expression in ER-positive 
endometrial cancer were evaluated from publicly available The Cancer Genome 
Atlas (TCGA) RNA-seq V2 dataset (normal, 22 samples and endometrial tissue, 
177 samples) and Gene Expression Omnibus database (GSE17025; normal, 12 
samples and endometrial tissue, 80 samples). 
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